Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Clearside Biomedi (CLSD)

Clearside Biomedi (CLSD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,912
  • Shares Outstanding, K 75,844
  • Annual Sales, $ 8,230 K
  • Annual Income, $ -32,490 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 2.33
  • Price/Sales 9.40
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 225.80% ( -19.47%)
  • Historical Volatility 69.62%
  • IV Percentile 60%
  • IV Rank 25.16%
  • IV High 855.81% on 05/02/24
  • IV Low 14.03% on 10/15/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 3,861
  • Open Int (30-Day) 4,120

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.13
  • Number of Estimates 3
  • High Estimate -0.12
  • Low Estimate -0.13
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9757 +10.69%
on 11/15/24
1.1600 -6.90%
on 11/12/24
-0.0200 (-1.82%)
since 10/25/24
3-Month
0.9200 +17.39%
on 09/05/24
1.6500 -34.55%
on 10/09/24
+0.0600 (+5.88%)
since 08/23/24
52-Week
0.9200 +17.39%
on 09/05/24
2.1200 -49.06%
on 03/12/24
+0.0700 (+6.93%)
since 11/24/23

Most Recent Stories

More News
Clearside Biomedical, Inc. Highlights Leadership in Suprachoroidal Delivery at Asia-Pacific Vitreo-Retina Society Congress

Clearside Biomedical showcased its suprachoroidal delivery technology and pipeline results at the Asia-Pacific Vitreo-Retina Society Congress.Quiver AI SummaryClearside Biomedical, Inc. announced its leadership...

CLSD : 1.0800 (unch)
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

CLSD : 1.0800 (unch)
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

CLSD : 1.0800 (unch)
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

CLSD : 1.0800 (unch)
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

CLSD : 1.0800 (unch)
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

CLSD : 1.0800 (unch)
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

CLSD : 1.0800 (unch)
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

CLSD : 1.0800 (unch)
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

CLSD : 1.0800 (unch)
Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty...

CLSD : 1.0800 (unch)

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious...

See More

Key Turning Points

3rd Resistance Point 1.1733
2nd Resistance Point 1.1467
1st Resistance Point 1.1133
Last Price 1.0800
1st Support Level 1.0533
2nd Support Level 1.0267
3rd Support Level 0.9933

See More

52-Week High 2.1200
Fibonacci 61.8% 1.6616
Fibonacci 50% 1.5200
Fibonacci 38.2% 1.3784
Last Price 1.0800
52-Week Low 0.9200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar